StockNow
Log in
Global Markets

Genmab (GMAB DC) H1 2026 (USD): EBIT 555mln, sees FY gross profit of 4.015-4.195bln

StockNow breaking-news AI analysis

Genmab reported H1 2026 EBIT of $555 million and projected full-year gross profit of $4.015-$4.195 billion, reflecting continued scale-up of its oncology portfolio following strong 2025 growth.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Yemeni Armed Forces Spokesman says will announce a large-scale and significant military operation

Geopolitics

Yemeni Houthi statement due at 15:30 BST/ 10:30 ET

Geopolitics

Details of the initial text of the strategic plan for managing the Strait of Hormuz: The passage of vessels belonging to the US, the Israelis, and other hostile countries through the Strait of Hormuz will be prohibited